• SPX
  • $5,780.05
  • -0.21 %
  • -$11.99
  • DJI
  • $42,454.12
  • -0.14 %
  • -$57.88
  • N225
  • $39,583.10
  • 0.51 %
  • $202.28
  • FTSE
  • $8,237.73
  • -0.07 %
  • -$6.01
  • IXIC
  • $18,282.05
  • -0.05 %
  • -$9.57
Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News & Analysis

Ligand Pharmaceuticals Incorporated (LGND) Stock Price, News & Analysis

Currency in USD Disclaimer

$100.02

-$3.22

(-3.12%)

Day's range
$98.9
Day's range
$102.13
50-day range
$90.29
Day's range
$108.98
  • Country: US
  • ISIN: US53220K5048
52 wk range
$49.24
Day's range
$112.13


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 13.93
  • Piotroski Score 6.00
  • Grade Buy
  • Symbol (LGND)
  • Company Ligand Pharmaceuticals Incorporated
  • Price $100.02
  • Changes Percentage (-3.12%)
  • Change -$3.22
  • Day Low $98.90
  • Day High $102.13
  • Year High $112.13

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.

  • Last Earnings N/A
  • Ex-Dividend for 5/16 Dividend 07/02/2010
  • Dividend Payable N/A
  • Today N/A
  • Next Earnings (Estimated) 11/05/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $135.00
  • High Stock Price Target $144.00
  • Low Stock Price Target $90.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $5.35
  • Trailing P/E Ratio 15.21
  • Forward P/E Ratio 15.21
  • P/E Growth 15.21
  • Net Income $52.15 M

Income Statement

Quarterly

Annual

Latest News of LGND

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.